Intervention
MEDI4736
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 15 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
15 shownPaclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBCNCT03616886 · 2018-12-28
ACTIVE_NOT_RECRUITINGMEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived TumorsNCT02669914 · 2016-09-12
TERMINATEDA Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.NCT02734004 · 2016-03-17
ACTIVE_NOT_RECRUITINGA Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic MalignanciesNCT02572687 · 2016-02-19
COMPLETEDTrial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic CancersNCT02639026 · 2016-01-26
COMPLETEDA Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid TumoursNCT02586987 · 2015-12-28
COMPLETEDNeoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast CancerNCT02489448 · 2015-11-01
COMPLETEDStudy of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive TumoursNCT02454933 · 2015-07-15
COMPLETEDDouble Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLCNCT02273375 · 2015-02-24
COMPLETEDA Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)NCT02318277 · 2015-01-05
COMPLETEDA Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerNCT02125461 · 2014-05-07
COMPLETEDSAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerNCT02299999 · 2014-04-07
ACTIVE_NOT_RECRUITINGMEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).NCT02088112 · 2014-03-24
COMPLETEDA Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung CancerNCT02087423 · 2014-02-25
COMPLETEDA Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung CancerNCT02000947 · 2013-10-25
COMPLETEDCommon conditions
Non-Small Cell Lung Cancer6Breast Cancer3Lung Cancer3Colorectal Cancer2Gastroesophageal Cancer2Melanoma2Pancreatic Cancer2Biliary Tract Cancer1Breast1Breast Neoplasms1Cancer of Breast1Cancer of Kidney1Cancer of Ovary1Cancer of the Breast1Cancer of the Kidney1Cancer of the Ovary1Cancer of the Pancreas1Carcinoma, Non-Small-Cell Lung1Colorectal Carcinoma1Gastric Cancer1Gastric Cancers1Gastroesophageal Junction Adenocarcinoma1Head and Neck Cancer1Head and Neck Carcinoma1Hepatocellular Carcinoma1
Leading sponsors
Trial status mix
COMPLETED11
ACTIVE_NOT_RECRUITING3
TERMINATED1
Phase mix
PHASE19
PHASE27
PHASE33
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.